Branchpoint Biosciences utilizes qMA™ technology, a quantitative PCR-based method, to provide rapid and precise quantification of target microorganisms in microbiome research. This approach enables researchers and clinicians to obtain accurate insights into microbiome composition and function, facilitating faster discoveries without the need for extensive bioinformatics.
Funding
Funding not disclosed
Founders
Product
Problem
Microbiome research is often hindered by traditional profiling methods that are either slow, lack precision, or require extensive bioinformatics analysis. Researchers and clinicians need faster, more accurate, and cost-effective tools to quantify microorganisms and understand microbiome composition and function.
Solution
Branchpoint Biosciences offers qMA™ technology, a quantitative PCR (qPCR)-based method, for rapid and precise quantification of target microorganisms in microbiome samples. These lab-validated, species-specific qPCR assays provide researchers and clinicians with accurate insights into microbiome composition without the need for complex bioinformatics. The company's qPCR products and services are designed to accelerate microbiome discovery and enable deeper understanding of microbial communities. Branchpoint Biosciences also offers custom qPCR assay design services tailored to specific research needs.
Target Audience
The primary audience includes microbiome researchers and clinicians seeking rapid, precise, and affordable quantification of microorganisms for research, product design, and quality control protocols.
Features
- qMA™: Lab-validated, species-specific qPCR assays (forward and reverse primers and fluorogenic probe) for quantitative detection of microorganisms.
- Compatible with all commercial real-time PCR machines.
- Over 120+ validated microbial species currently available, with more under development.
- Custom qPCR assay design service tailored to a desired level of phylogenetic resolution for a specific target.
- Products in development (Coming 2025): qMP.Oral™, qMP.UrinaryTract™ (2026), and qMP.Vaginal™ (2026) for quantitative microbiome profiling of prevalent bacterial and archaeal species.